A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of Cizutamig in Patients With Thyroid Eye Disease
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The purpose of this study is to evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of cizutamig in patients with thyroid eye disease (TED).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• 18-75 years old at the time of signing the Informed Consent Form
• Diagnosis of Graves' Disease with active, moderate to severe TED in accordance with the Chinese Guidelines for the Diagnosis and Treatment of Thyroid-Associated Ophthalmology (2022) at Screening and Day 1
Locations
Other Locations
China
Shanghai Ninth People's hospital Shanghai Jiaotong University school of medicines
RECRUITING
Shanghai
Contact Information
Primary
Martin Zhuang
martin@candidrx.com
+86 13918519658
Time Frame
Start Date: 2026-05-08
Estimated Completion Date: 2028-06-30
Participants
Target number of participants: 38
Treatments
Experimental: Cizutamig
Related Therapeutic Areas
Sponsors
Leads: Candid Therapeutics